Latest news and press releases about Puma Biotechnology, Inc. (PBYI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
Price
| Price | $9.39 |
| Market Cap | $478M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 16.72 |
| Price / Book | 3.30 |
| EV / EBITDA | 9.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 20.85% |
| Return on Invested Capital | 18.20% |
| Return on Assets | 13.86% |
| Gross Margin | 74.83% |
| Operating Margin | 13.16% |
| Net Margin | 11.55% |
Related companies: ABEO · ALLO · ARCT · AVIR · ELDN · HUMA · SGMT
Explore sector: Healthcare · Biotechnology
More sections of PBYI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks